Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias

Next Previous
Trial Profile

A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobomarsen (Primary) ; Cobomarsen (Primary) ; Cobomarsen (Primary) ; Cobomarsen (Primary)
  • Indications Adult T-cell leukaemia-lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Mycosis fungoides
  • Focus Adverse reactions; First in man
  • Sponsors miRagen Therapeutics; Viridian Therapeutics

Most Recent Events

  • 19 Nov 2020 Status changed from active, no longer recruiting to completed.
  • 05 Aug 2020 According to a miRagen Therapeutics media release, the company plans to meet with the FDA and receive guidance on the Company's proposed clinical path in this indication before the end of 2020.
  • 07 May 2020 According to a miRagen Therapeutics media release, the Company would expect to meet with the FDA in the third quarter of 2020. However, as the FDA prioritizes its efforts on COVID-19, it is uncertain if the meeting will occur on the standard FDA timeline. The Company therefore cannot provide assurances that the meeting will occur as originally expected in the third quarter of 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top